HALO
NASDAQ · Biotechnology
Halozyme Therapeutics Inc
$111.45
-1.00 (-0.89%)
Financial Highlights (FY 2026)
Revenue
1.27B
Net Income
288.75M
Gross Margin
83.6%
Profit Margin
22.7%
Rev Growth
+28.4%
D/E Ratio
43.89
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 83.6% | 83.6% | 67.3% | 67.3% |
| Operating Margin | 33.2% | 29.9% | -6.4% | -7.2% |
| Profit Margin | 22.7% | 21.6% | -5.8% | -7.2% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 1.27B | 991.28M | 1.30B | 1.05B |
| Gross Profit | 1.06B | 828.91M | 873.05M | 707.65M |
| Operating Income | 422.38M | 296.10M | -82,975,143 | -75,519,990 |
| Net Income | 288.75M | 202.43M | -74,995,325 | -75,300,768 |
| Gross Margin | 83.6% | 83.6% | 67.3% | 67.3% |
| Operating Margin | 33.2% | 29.9% | -6.4% | -7.2% |
| Profit Margin | 22.7% | 21.6% | -5.8% | -7.2% |
| Rev Growth | +28.4% | +28.4% | +13.4% | +1.2% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 6.21B | 6.21B | 2.05B | 2.54B |
| Total Equity | 141.40M | 141.40M | 5.54B | 5.77B |
| D/E Ratio | 43.89 | 43.89 | 0.37 | 0.44 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | 492.23M | 364.25M | -91,476,031 | -72,949,593 |
| Free Cash Flow | — | — | -86,399,966 | -67,262,012 |